Evidence map›Paper›PMID 32267841›Full record

ArticlePloS one2020

Influence of sickle cell disease on susceptibility to HIV infection.

Shannon Kelly, Evan S Jacobs, Mars Stone, Sheila M Keating, Tzong-Hae Lee, Daniel Chafets, John Heitman, Melanie Dimapasoc, Eva Operskalski, Ward Hagar and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Does Sickle Cell Disease Protect against HIV Infection: A Systematic Review.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Shannon KellyVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0003-2049-3992
Evan S JacobsVitalant Research Institute, San Francisco, CA, United States of America.
Mars StoneVitalant Research Institute, San Francisco, CA, United States of America.
Sheila M KeatingVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0002-8324-3694
Tzong-Hae LeeVitalant Research Institute, San Francisco, CA, United States of America.
Daniel ChafetsVitalant Research Institute, San Francisco, CA, United States of America.
John HeitmanVitalant Research Institute, San Francisco, CA, United States of America.
Melanie DimapasocVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0003-0328-315X
Eva OperskalskiKeck School of Medicine, University of Southern California, Los Angeles, CA, United States of America.
Ward HagarUCSF Benioff Children's Hospital Oakland, Oakland, CA, United States of America.
Elliott VichinskyUCSF Benioff Children's Hospital Oakland, Oakland, CA, United States of America.
Michael P BuschVitalant Research Institute, San Francisco, CA, United States of America.
Philip J NorrisVitalant Research Institute, San Francisco, CA, United States of America.ORCID 0000-0003-0526-2088
Brian CusterVitalant Research Institute, San Francisco, CA, United States of America.
Recipient Epidemiology and Donor Evaluation Study (REDS-III)
Vitalant · USUCSF Benioff Children's Hospital · USUniversity of Southern California · US

Funding

NHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007I
6 · The paper itself

Abstract

People with sickle cell disease (SCD) are reported to have low rates of HIV infection, slower progression to AIDS and lower HIV-associated mortality compared to the general population. Mechanisms of potential resistance to HIV in SCD are incompletely understood. We retrospectively reviewed the Transfusion Safety Study to compare HIV status between people with SCD and other congenital anemias who were routinely exposed to blood products during the high-risk period before HIV screening implementation. Non-SCD congenital anemia diagnosis was associated with a higher risk of HIV acquisition compared to SCD (OR 13.1 95%CI 1.6-108.9). In addition, we prospectively enrolled 30 SCD cases and 30 non-SCD controls to investigate potential mechanisms of resistance to HIV in SCD. CCR5 and CCR7 expression was lower and CD4 expression was higher on CD4+ T cells from SCD cases compared to controls. Surface expression of CD4+ T cell CXCR4, CD38 and HLA-DR did not differ between the groups. SCD CD4+ T cells were not less susceptible to HIV infection than controls. Levels of multiple cytokines were elevated in the SCD plasma, but SCD plasma compared to control plasma did not inhibit HIV infection of target cells. In conclusion, our epidemiological data support people with SCD being resistant to HIV infection. Potential mechanisms include lower CD4+ T cell expression of CCR5 and CCR7, balanced by increased CD4 expression and cytokine levels, which did not result in in vitro resistance to HIV infection. Further study is needed to define the risk and pathophysiology of HIV in persons with SCD.

Indexed as

AdolescentAdultAnemia, Sickle CellBlood SafetyBlood TransfusionCD4-Positive T-LymphocytesCell LineCytokinesDisease SusceptibilityFemaleHIVHIV InfectionsHumansMaleMiddle AgedProspective StudiesCytokines

Identifiers

PMID32267841
PMCPMC7141606
OpenAlexW3014475237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.